Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07461454) titled 'YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Condition:
Locally Advanced or Metastatic Breast Cancer
Intervention:
Drug: YL202
Drug: Eribulin
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 10, 2026
Target Sample Size: 376
Countries of Recruitme...